Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Bladder Cancer, March 2017

Free Subscription


Abstracts

Retrieve all available abstracts of the following 116 articles:
HTML format


 

Single Articles

  1. BAGAYOGO T, Jakhal N, Slaoui A, Ziouziou I, et al
    [Neoplastic Vesico-vaginal Fistula (VVF) secondary to bladder cancer: a rare entity].
    Pan Afr Med J. 2016;25:59.
    Abstract    

    Abstract available

  2. KAMAT AM, Colombel M, Sundi D, Lamm D, et al
    BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG.
    Nat Rev Urol. 2017 Feb 21. doi: 10.1038/nrurol.2017.
    Abstract    

    Abstract available

  3. YARMOSHCHUK SV, Kudryavtsev AS, Zeravin AA, Drobyazgin EA, et al
    [Robot-assisted cystprostatectomy for urinary bladder cancer (the first experience)].
    Urologiia. 2016;:132-135.
    Abstract    

    Abstract available

  4. PAVLOV VN, Pushkaryev AM, Safiullin RI, Kazikhinurov AA, et al
    [Experience with radical surgery for muscle-invasive bladder cancer in patients with end-stage chronic kidney disease].
    Urologiia. 2016;:124-127.
    Abstract    

    Abstract available

  5. ALYAEV YG, Pshikhachev AM, Perekalina AN
    [The risk of bladder cancer in patients with prostatic hyperplasia and strategies to manage this combination].
    Urologiia. 2016;:115-118.
    Abstract    

    Abstract available

  6. GLYBOCHKO PV, Alyaev YG, Pshikhachev AM, Sorokin NI, et al
    [Choosing treatment for patients with bladder cancer combined with prostatic hyperplasia].
    Urologiia. 2016;:92-96.
    Abstract    

    Abstract available

  7. ROLEVICH AI, Evmenenko AA
    [A systematic review and meta-analysis to assess the recurrence-free survival in non-muscle invasive bladder cancer after transurethral resection guided by 5-aminolevulinic acid-induced photodynamic diagnosis compared with white-light transurethral re
    Urologiia. 2016;:137-146.
    Abstract    

    Abstract available

  8. GLYBOCHKO PV, Alyaev JG, Potoldykova NV, Polyakovsky KA, et al
    [The role of telomerase activity in non-invasive diagnostics of bladder cancer].
    Urologiia. 2016;:76-81.
    Abstract    

    Abstract available

  9. MIKHAILENKO DS, Nemtsova MV
    [Point somatic mutations in bladder cancer: key carcinogenesis events, diagnostic markers and therapeutic targets].
    Urologiia. 2016;:100-105.
    Abstract    

    Abstract available

  10. ROLEVICH AI
    [The criteria of patient selection for repeat transurethral resection of non-muscle invasive bladder cancer].
    Urologiia. 2016;:71-76.
    Abstract    

    Abstract available

  11. KOSOVA IV
    [The role of viruses in the etiology of bladder cancer].
    Urologiia. 2016;:100-103.
    Abstract    

    Abstract available

  12. FENG S, Chen J, Zheng Y
    [Research progress on the effect of glucocorticoid receptor signaling pathways in bladder cancer].
    Zhejiang Da Xue Xue Bao Yi Xue Ban. 2016;45:655-660.
    Abstract    

    Abstract available

  13. YOSHIDA S, Takahara T, Kwee TC, Waseda Y, et al
    DWI as an Imaging Biomarker for Bladder Cancer.
    AJR Am J Roentgenol. 2017 Feb 28:1-11. doi: 10.2214/AJR.17.17798.
    Abstract    

    Abstract available

  14. REDDY AV, Christodouleas JP, Wu T, Smith ND, et al
    External Validation and Optimization of International Consensus Clinical Target Volumes for Adjuvant Radiation Therapy in Bladder Cancer.
    Int J Radiat Oncol Biol Phys. 2017;97:740-746.
    Abstract    

    Abstract available

  15. THOMPSON C, Joseph N, Sanderson B, Logue J, et al
    Tolerability of Concurrent Chemoradiation Therapy With Gemcitabine (GemX), With and Without Prior Neoadjuvant Chemotherapy, in Muscle Invasive Bladder Cancer.
    Int J Radiat Oncol Biol Phys. 2017;97:732-739.
    Abstract    

    Abstract available

  16. PARK SJ, Myung SK, Lee Y, Lee YJ, et al
    Effects of Vitamin and Antioxidant Supplements in Prevention of Bladder Cancer: a Meta-Analysis of Randomized Controlled Trials.
    J Korean Med Sci. 2017;32:628-635.
    Abstract    

    Abstract available

  17. SOLANKI AA, Martin B, Korpics M, Small C, et al
    Adjuvant Radiotherapy Use by US Radiation Oncologists After Radical Cystectomy for Muscle-invasive Bladder Cancer.
    Clin Oncol (R Coll Radiol). 2017 Feb 24. pii: S0936-6555(17)30080.
    Abstract    

    Abstract available

  18. LI P, Chen J, Miyamoto H
    Androgen Receptor Signaling in Bladder Cancer.
    Cancers (Basel). 2017;9.
    Abstract    

    Abstract available

  19. MIGITA T, Ueda A, Ohishi T, Hatano M, et al
    Epithelial-mesenchymal transition promotes SOX2 and NANOG expression in bladder cancer.
    Lab Invest. 2017 Feb 27. doi: 10.1038/labinvest.2017.
    Abstract    

    Abstract available

  20. COGORNO WASYLKOWSKI L, Rios-Gonzalez E, Linares Espinos E, Leibar Tamayo A, et al
    Indication for early cystectomy in nonmuscle-invasive bladder cancer. Literature review.
    Actas Urol Esp. 2017 Feb 18. pii: S0210-4806(17)30004.
    Abstract    

    Abstract available

  21. APFELTHALER C, Anzengruber M, Gabor F, Wirth M, et al
    Poly - (L) - glutamic acid drug delivery system for the intravesical therapy of bladder cancer using WGA as targeting moiety.
    Eur J Pharm Biopharm. 2017 Feb 22. pii: S0939-6411(16)30583.
    Abstract    

    Abstract available

  22. HENON C, Huillard O, Preta LH, Blanchet B, et al
    Cytidine Deaminase Activity Assessment to Select Perioperative Chemotherapy Regimen in Localized Bladder Cancer.
    Clin Genitourin Cancer. 2017 Feb 1. pii: S1558-7673(17)30033.
    Abstract    



  23. ISMAIL AF, Oskay S, Babteen N, De Piano M, et al
    PAK5 mediates cell:cell adhesion integrity via interaction with E-cadherin in bladder cancer cells.
    Biochem J. 2017 Feb 23. pii: BCJ20160875. doi: 10.1042/BCJ20160875.
    Abstract    

    Abstract available

  24. YU HT, Kim TH, Uhm JS, Kim JY, et al
    Clinical Significance of Hematuria in Atrial Fibrillation With Oral Anticoagulation Therapy.
    Circ J. 2017;81:158-164.
    Abstract    

    Abstract available

  25. WU YP, Lin TT, Chen SH, Xu N, et al
    Comparison of the efficacy and feasibility of en bloc transurethral resection of bladder tumor versus conventional transurethral resection of bladder tumor: A meta-analysis.
    Medicine (Baltimore). 2016;95:e5372.
    Abstract    

    Abstract available

  26. KIM C, Gao J, Shannon VR, Siefker-Radtke A, et al
    Systemic sarcoidosis first manifesting in a tattoo in the setting of immune checkpoint inhibition.
    BMJ Case Rep. 2016;2016.
    Abstract    

    Abstract available

  27. KEHILA M, Mekni K, Abouda HS, Chtourou M, et al
    [Leiomyoma of the bladder causing the destruction of a kidney].
    Pan Afr Med J. 2016;24:10.
    Abstract    

    Abstract available

  28. KITAYAMA H, Yokota T, Kondo T, Sugiyama J, et al
    Unusual Development of Pulmonary Tumor Embolism from Controlled Liver Metastases of Transitional Cell Carcinoma: An Autopsy Case.
    Intern Med. 2016;55:2453-6.
    Abstract    

    Abstract available

  29. GUO XG, Long JJ
    Cytokeratin-19 fragment in the diagnosis of bladder carcinoma.
    Tumour Biol. 2016;37:14329-14330.
    Abstract    

    Abstract available

  30. KOUBA E, Cheng L
    Neuroendocrine Tumors of the Urinary Bladder According to the 2016 World Health Organization Classification: Molecular and Clinical Characteristics.
    Endocr Pathol. 2016;27:188-99.
    Abstract    

    Abstract available

  31. HASSAN M, Qureshi A, Nasir H
    Recurrent verrucous carcinoma of the urinary bladder after transurethral resection followed by intravesical mitomycin, and a review of the literature.
    BMJ Case Rep. 2016;2016.
    Abstract    

    Abstract available

  32. XING QW, Wu Y, Cai B, Ma LM, et al
    [Clinical research of second resection on early stage primary bladder adenocarcinoma and literature review].
    Zhonghua Yi Xue Za Zhi. 2016;96:1585-7.
    Abstract    

    Abstract available

  33. GUPTA S, Zhang J, Rivera M, Erickson LA, et al
    Urinary Bladder Paragangliomas: Analysis of Succinate Dehydrogenase and Outcome.
    Endocr Pathol. 2016;27:243-52.
    Abstract    

    Abstract available

  34. OU X, Hong F, Zhang Z, Cheng Y, et al
    A highly sensitive and facile graphene oxide-based nucleic acid probe: Label-free detection of telomerase activity in cancer patient's urine using AIEgens.
    Biosens Bioelectron. 2017;89.
    Abstract    

    Abstract available

  35. RIZOS CV, Kei A, Elisaf MS
    The current role of thiazolidinediones in diabetes management.
    Arch Toxicol. 2016;90:1861-81.
    Abstract    

    Abstract available

  36. KIM M, Kim YY, Jee HJ, Bae SS, et al
    Akt3 knockdown induces mitochondrial dysfunction in human cancer cells.
    Acta Biochim Biophys Sin (Shanghai). 2016;48:447-53.
    Abstract    

    Abstract available

  37. CANDIDO S, Di Maso M, Serraino D, McCubrey JA, et al
    Diagnostic value of neutrophil gelatinase-associated lipocalin/matrix metalloproteinase-9 pathway in transitional cell carcinoma of the bladder.
    Tumour Biol. 2016;37:9855-63.
    Abstract    

    Abstract available

  38. ISLAM SS, Mokhtari RB, Akbari P, Hatina J, et al
    Simultaneous Targeting of Bladder Tumor Growth, Survival, and Epithelial-to-Mesenchymal Transition with a Novel Therapeutic Combination of Acetazolamide (AZ) and Sulforaphane (SFN).
    Target Oncol. 2016;11:209-27.
    Abstract    

    Abstract available

  39. KAHOKEHR A, Glasson J, Studd R
    Surgical waiting time for radical cystectomy: a New Zealand experience.
    ANZ J Surg. 2016;86:1042-1045.
    Abstract    

    Abstract available

  40. SINGLA M, Shikha D, Lee S, Baumstein D, et al
    Ileal Neobladder With Mucous Plugs as a Cause of Obstructive Acute Kidney Injury Requiring Emergent Hemodialysis.
    Am J Ther. 2016;23:e1099-101.
    Abstract    

    Abstract available

  41. YAO HH, Chu K, Hallot C, Lewin J, et al
    Metachronous primary urothelial carcinoma following small cell carcinoma of the urinary bladder.
    ANZ J Surg. 2017;87.
    Abstract    



  42. WU C, Zhou X, Miao C, Zhang J, et al
    Assessing the Feasibility of Replacing Standard-Dose Bacillus Calmette-Guerin Immunotherapy with Other Intravesical Instillation Therapies in Bladder Cancer Patients: A Network Meta-Analysis.
    Cell Physiol Biochem. 2017;41:1298-1312.
    Abstract    

    Abstract available

  43. QIU W, Lin J, Zhu Y, Zhang J, et al
    Kaempferol Modulates DNA Methylation and Downregulates DNMT3B in Bladder Cancer.
    Cell Physiol Biochem. 2017;41:1325-1335.
    Abstract    

    Abstract available

  44. ATTA MA, Kotb AF, Sharafeldeen M, Elabbady A, et al
    The value of extended good quality transurethral resection of bladder tumour in the treatment of the newly diagnosed bladder cancer.
    Arab J Urol. 2016;15:60-63.
    Abstract    

    Abstract available

  45. BUISAN O, Orsola A, Oliveira M, Martinez R, et al
    Role of Inflammation in the Perioperative Management of Urothelial Bladder Cancer With Squamous-Cell Features: Impact of Neutrophil-to-Lymphocyte Ratio on Outcomes and Response to Neoadjuvant Chemotherapy.
    Clin Genitourin Cancer. 2017 Feb 6. pii: S1558-7673(17)30040.
    Abstract    

    Abstract available

  46. YIN X, Li F, Jin Y, Yin Z, et al
    [Establishment of a human bladder cancer cell line stably co-expressing hSPRY2 and luciferase genes and its subcutaneous tumor xenograft model in nude mice].
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2017;33:337-341.
    Abstract    

    Abstract available

  47. ISMAILI N
    Neoadjuvant Chemotherapy: A New Standard for Muscle Invasive Bladder Cancer?
    Gulf J Oncolog. 2017;1:82-85.
    Abstract    

    Abstract available

  48. KILINC MF, Bayar G, Dalkilic A, Sonmez NC, et al
    Applicability of the EORTC risk tables to predict outcomes in non-muscle-invasive bladder cancer in Turkish patients.
    Turk J Urol. 2017;43:48-54.
    Abstract    

    Abstract available

  49. KAMAT AM, Bagcioglu M, Huri E
    What is new in non-muscle-invasive bladder cancer in 2016?
    Turk J Urol. 2017;43:9-13.
    Abstract    

    Abstract available

  50. YUAN Q, Sun T, Ye F, Kong W, et al
    MicroRNA-124-3p affects proliferation, migration and apoptosis of bladder cancer cells through targeting AURKA.
    Cancer Biomark. 2017 Feb 27. doi: 10.3233/CBM-160427.
    Abstract    

    Abstract available

  51. SHEPHERD AR, Shepherd E, Brook NR
    Intravesical Bacillus Calmette-Guerin with interferon-alpha versus intravesical Bacillus Calmette-Guerin for treating non-muscle-invasive bladder cancer.
    Cochrane Database Syst Rev. 2017;3:CD012112.
    Abstract    

    Abstract available

  52. SHANG A, Yang M, Shen F, Wang J, et al
    MiR-1-3p Suppresses the Proliferation, Invasion and Migration of Bladder Cancer Cells by Up-Regulating SFRP1 Expression.
    Cell Physiol Biochem. 2017;41:1179-1188.
    Abstract    

    Abstract available

  53. HWANG EC, Jung SI, Lee HJ, Lee JJ, et al
    Generation of potent cytotoxic T lymphocytes against in male patients with non-muscle invasive bladder cancer by dendritic cells loaded with dying T24 bladder cancer cells.
    Int Braz J Urol. 2017;43.
    Abstract    

    Abstract available

  54. SIDAWAY P
    Bladder cancer: Pembrolizumab is superior to chemotherapy.
    Nat Rev Urol. 2017 Mar 7. doi: 10.1038/nrurol.2017.
    Abstract    



  55. TYSON MD, Chang SS, Keegan KA
    Role of consolidative surgical therapy in patients with locally advanced or regionally metastatic bladder cancer.
    Bladder (San Franc). 2016;3.
    Abstract    

    Abstract available

  56. YURUK E, Saitz TR, Gonultas S, Serefoglu EC, et al
    Neutrophil-to-lymphocyte ratio is elevated in recurringnonmuscle invasive bladder cancer.
    Turk J Med Sci. 2017;47:234-239.
    Abstract    

    Abstract available

  57. MAHDAVINEZHAD A, Yadegarazari R, Mousavi-Bahar SH, Poorolajal J, et al
    Evaluation of zinc finger E-box binding homeobox 1 and transforming growth factor-beta2 expression in bladder cancer tissue in comparison with healthy adjacent tissue.
    Investig Clin Urol. 2017;58:140-145.
    Abstract    

    Abstract available

  58. ZHAO ZF, Wang K, Guo FF, Lu H, et al
    Inhibition of T24 and RT4 Human Bladder Cancer Cell Lines by Heterocyclic Molecules.
    Med Sci Monit. 2017;23:1156-1164.
    Abstract    

    Abstract available

  59. MUPPA P, Gupta S, Frank I, Boorjian SA, et al
    Prognostic significance of lymphatic, vascular and perineural invasion for bladder cancer patients treated by radical cystectomy.
    Pathology. 2017 Mar 1. pii: S0031-3025(16)40358.
    Abstract    

    Abstract available

  60. YIN H, Qin C, Zhao Y, Du Y, et al
    SOX10 is over-expressed in bladder cancer and contributes to the malignant bladder cancer cell behaviors.
    Clin Transl Oncol. 2017 Mar 3. doi: 10.1007/s12094-017-1641.
    Abstract    

    Abstract available

  61. MIYAKE M, Hori S, Morizawa Y, Tatsumi Y, et al
    Corrigendum to "CXCL1-Mediated Interaction of Cancer Cells with Tumor-Associated Macrophages and Cancer-Associated Fibroblasts Promotes Tumor Progression in Human Bladder Cancer" [Neoplasia 18 (2016) 636-646].
    Neoplasia. 2017;19:250-251.
    Abstract    



  62. SANGUEDOLCE F, Loizzi D, Sollitto F, Di Bisceglie M, et al
    Bladder Metastases from Lung Cancer: Clinical and Pathological Implications: A Systematic Review.
    Oncology. 2017;92:125-134.
    Abstract    

    Abstract available

  63. KUMAR V, Garg R, Gupta N, Bharati SJ, et al
    Cautious use and optimal dose of morphine for relieving malignant pain in a complex patient with multiple comorbidities.
    BMJ Case Rep. 2016;2016.
    Abstract    

    Abstract available

  64. TORRES-BLANCO A, Gomez-Palones F, Edo-Fleta G
    Arteriocutaneous Fistula Associated with Bilateral Femoral Pseudoaneurysms Caused by Bacillus Calmette-Guerin. Apropos of a Case and Review of Literature.
    Ann Vasc Surg. 2017;39:291.
    Abstract    

    Abstract available

  65. PIVOVARCIKOVA K, Pitra T, Vanecek T, Alaghehbandan R, et al
    Comparative study of TERT gene mutation analysis on voided liquid-based urine cytology and paraffin-embedded tumorous tissue.
    Ann Diagn Pathol. 2016;24:7-10.
    Abstract    



  66. ALONGI P, Caobelli F, Gentile R, Stefano A, et al
    Recurrent bladder carcinoma: clinical and prognostic role of 18 F-FDG PET/CT.
    Eur J Nucl Med Mol Imaging. 2017;44:224-233.
    Abstract    

    Abstract available

  67. MADANCHI M, Zeitz J, Barthel C, Samaras P, et al
    Malignancies in Patients with Inflammatory Bowel Disease: A Single-Centre Experience.
    Digestion. 2016;94:1-8.
    Abstract    

    Abstract available

  68. YU R, Gohla G, Haider EA
    Chromophobe renal cell carcinoma mimicking cortical invasion by synchronous invasive urothelial carcinoma of the intra-renal collecting system on CT urography.
    Int Braz J Urol. 2016;42:392-4.
    Abstract    



  69. ARISTA-NASR J, Martinez-Benitez B, Bornstein-Quevedo L, Aguilar-Ayala E, et al
    Low grade urothelial carcinoma mimicking basal cell hyperplasia and transitional metaplasia in needle prostate biopsy.
    Int Braz J Urol. 2016;42:247-52.
    Abstract    

    Abstract available

  70. POLAT H, Utangac MM, Gulpinar MT, Cift A, et al
    Urothelial neoplasm of the bladder in childhood and adolescence: a rare disease.
    Int Braz J Urol. 2016;42:242-6.
    Abstract    

    Abstract available

  71. DING XL, Yang X, Liang G, Wang K, et al
    Isoform switching and exon skipping induced by the DNA methylation inhibitor 5-Aza-2'-deoxycytidine.
    Sci Rep. 2016;6:24545.
    Abstract    

    Abstract available

  72. DAHM HH, von der Haar C, Rubben H
    DNA cytophotometric and histological analysis of N-butyl-N-(4-hydroxybutyl)nitrosamine-induced precancerous lesions of the bladder urothelium.
    J Cancer Res Clin Oncol. 2016;142:1253-60.
    Abstract    

    Abstract available

  73. TAMAS A, Javorhazy A, Reglodi D, Sarlos DP, et al
    Examination of PACAP-Like Immunoreactivity in Urogenital Tumor Samples.
    J Mol Neurosci. 2016;59:177-83.
    Abstract    

    Abstract available

  74. DAVARPANAH NN, Yuno A, Trepel JB, Apolo AB, et al
    Immunotherapy: a new treatment paradigm in bladder cancer.
    Curr Opin Oncol. 2017 Mar 16. doi: 10.1097/CCO.0000000000000366.
    Abstract    

    Abstract available

  75. LI QQ, Hao JJ, Zhang Z, Krane LS, et al
    Proteomic analysis of proteome and histone post-translational modifications in heat shock protein 90 inhibition-mediated bladder cancer therapeutics.
    Sci Rep. 2017;7:201.
    Abstract    

    Abstract available

  76. ROUDNICKY F, Dieterich LC, Poyet C, Buser L, et al
    High expression of insulin receptor on tumor-associated blood vessels in invasive bladder cancer predicts poor overall and progression-free survival.
    J Pathol. 2017 Mar 14. doi: 10.1002/path.4892.
    Abstract    

    Abstract available

  77. BOMAN K, Andersson G, Wennersten C, Nodin B, et al
    Podocalyxin-like and RNA-binding motif protein 3 are prognostic biomarkers in urothelial bladder cancer: a validatory study.
    Biomark Res. 2017;5:10.
    Abstract    

    Abstract available

  78. SEILER R, Black PC, Thalmann G, Stenzl A, et al
    Is The Cancer Genome Atlas (TCGA) bladder cancer cohort representative of invasive bladder cancer?
    Urol Oncol. 2017 Mar 10. pii: S1078-1439(17)30059.
    Abstract    

    Abstract available

  79. NGUYEN DP, Thalmann GN
    Contemporary update on neoadjuvant therapy for bladder cancer.
    Nat Rev Urol. 2017 Mar 14. doi: 10.1038/nrurol.2017.
    Abstract    

    Abstract available

  80. POTTS KG, Irwin CR, Favis NA, Pink DB, et al
    Deletion of F4L (ribonucleotide reductase) in vaccinia virus produces a selective oncolytic virus and promotes anti-tumor immunity with superior safety in bladder cancer models.
    EMBO Mol Med. 2017 Mar 13. pii: e201607296. doi: 10.15252/emmm.201607296.
    Abstract    

    Abstract available


  81. Immunotherapy Beats Chemo for Bladder Cancer.
    Cancer Discov. 2017 Mar 13. doi: 10.1158/2159-8290.CD-NB2017.
    Abstract    

    Abstract available

  82. DURIEZ E, Masselon CD, Mesmin C, Court M, et al
    Large-Scale SRM Screen of Urothelial Bladder Cancer Candidate Biomarkers in Urine.
    J Proteome Res. 2017 Mar 13. doi: 10.1021/acs.jproteome.6b00979.
    Abstract    

    Abstract available

  83. TYSON MD, Lee D, Clark P
    New developments in the management of nonmuscle invasive bladder cancer.
    Curr Opin Oncol. 2017 Mar 9. doi: 10.1097/CCO.0000000000000362.
    Abstract    

    Abstract available

  84. LI J, Qu W, Jiang Y, Sun Y, et al
    miR-489 Suppresses Proliferation and Invasion of Human Bladder Cancer Cells.
    Oncol Res. 2016;24:391-398.
    Abstract    

    Abstract available

  85. CICCARESE C, Massari F, Blanca A, Tortora G, et al
    Tp53 and its potential therapeutic role as a target in bladder cancer.
    Expert Opin Ther Targets. 2017;21:401-414.
    Abstract    

    Abstract available

  86. AZER SA, Alghofaili MM, Alsultan RM, Alrumaih NS, et al
    Accuracy and Readability of Websites on Kidney and Bladder Cancers.
    J Cancer Educ. 2017 Mar 9. doi: 10.1007/s13187-017-1181.
    Abstract    

    Abstract available

  87. PARK J, Shin DW, Kim TH, Jung SI, et al
    Development and Validation of the Korean Version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Patients with Non-muscle invasive bladder Cancer - EORTC QLQ-NMIBC24.
    Cancer Res Treat. 2017 Mar 10. doi: 10.4143/crt.2016.
    Abstract    

    Abstract available

  88. PATEL A, Desai P, Malczewski F, Stephens D, et al
    Mullerianosis of the urinary bladder: a rare and problematic bladder tumour.
    BMJ Case Rep. 2017;2017.
    Abstract    

    Abstract available

  89. ZHANG YG, Song QX, Song B, Zhang DL, et al
    Diagnosis and Treatment of Urinary Incontinence after Orthotopic Ileal Neobladder in China.
    Chin Med J (Engl). 2017;130:231-235.
    Abstract    



  90. LIANG X, Men QL, Li YW, Li HC, et al
    Silencing of Armadillo Repeat-Containing Protein 8 (ARMc8) Inhibits TGF-beta-Induced EMT in Bladder Carcinoma UMUC3 Cells.
    Oncol Res. 2017;25:99-105.
    Abstract    

    Abstract available

  91. KUMAR AV, Mogili HK, Boju SL, Guptha R, et al
    Pheochromocytoma of Urinary Bladder in a Dialysis PatientPheochromocytoma of Urinary Bladder.
    Nephrology (Carlton). 2017;22:183.
    Abstract    



  92. KIM CJ, Fujiwara R, Yamashita H
    [Modified Toyoda Method for Complete Duplex Ureters in Tubeless Cutaneous Ureterostomy : Report of a Case].
    Hinyokika Kiyo. 2016;62:591-594.
    Abstract    

    Abstract available

  93. OWARI T, Yamamoto T, Mizobuchi S, Itami Y, et al
    [Bladder Metastasis of Renal Cell Carcinoma 7 Years after Ex Vivo Partial Nephrectomy and Auto-Transplantation : A Case Report].
    Hinyokika Kiyo. 2016;62:575-579.
    Abstract    

    Abstract available

  94. TOPAL CS, Kir G, Das T, Sarbay B, et al
    Metastatic malignant melanoma of the urinary bladder: A case report and review of the literature.
    Indian J Pathol Microbiol. 2016;59:532-534.
    Abstract    

    Abstract available

  95. SINGH JP, Priyadarshi V, Pal DK
    A clinicoepidemiological study of young age bladder tumors: An eastern Indian scenario.
    J Cancer Res Ther. 2016;12:751-4.
    Abstract    

    Abstract available

  96. WANG HJ, Pui MH, Guo Y, Guan J, et al
    Preliminary study of diffusion-weighted MRI in the preoperative diagnosis of cystitis glandularis.
    Clin Radiol. 2016;71:937.
    Abstract    

    Abstract available

  97. SARSIK B, Doganavsargil B, Simsir A, Yazici A, et al
    P21 and p27 Immunoexpression in Upper Urinary Tract Urothelial Carcinomas.
    Pathol Oncol Res. 2016;22:839-45.
    Abstract    

    Abstract available

  98. VANDENBUSSCHE CJ
    A review of the Paris system for reporting urinary cytology.
    Cytopathology. 2016;27:153-6.
    Abstract    

    Abstract available

  99. PRABHU B, Sivakumar A, Sundaresan S
    Diindolylmethane and Lupeol Modulates Apoptosis and Cell Proliferation in N-Butyl-N-(4-Hydroxybutyl) Nitrosamine Initiated and Dimethylarsinic Acid Promoted rat Bladder Carcinogenesis.
    Pathol Oncol Res. 2016;22:747-54.
    Abstract    

    Abstract available

  100. WU D, Wang Y, Zhang Y, Ma H, et al
    Sensitive Electrochemical Immunosensor for Detection of Nuclear Matrix Protein-22 based on NH2-SAPO-34 Supported Pd/Co Nanoparticles.
    Sci Rep. 2016;6:24551.
    Abstract    

    Abstract available

  101. ROSS EM, Markowetz F
    OncoNEM: inferring tumor evolution from single-cell sequencing data.
    Genome Biol. 2016;17:69.
    Abstract    

    Abstract available

  102. WU CL, Svendsen SG, Riviere A, Desgrandchamps F, et al
    Multiplex bead-based immunoassay for the free soluble forms of the HLA-G receptors, ILT2 and ILT4.
    Hum Immunol. 2016;77:720-6.
    Abstract    

    Abstract available

  103. FRIEDMAN P, Lai JP
    Liver Metastasis of Urothelial Carcinoma with Hepatoid Features: An Unusual Morphological Finding.
    Anticancer Res. 2017;37:801-804.
    Abstract    

    Abstract available

  104. COTTE J, Roupret M
    Re: Long-term Oncological Outcomes of an Active Surveillance Program in Recurrent Low Grade Ta Bladder Cancer.
    Eur Urol. 2017 Feb 18. pii: S0302-2838(17)30106.
    Abstract    



  105. MAY M, Lebentrau S, Brookman-May SD
    Re: Decreased Overall and Bladder Cancer-specific Mortality with Adjuvant Chemotherapy After Radical Cystectomy: Multivariable Competing Risk Analysis.
    Eur Urol. 2017 Feb 20. pii: S0302-2838(17)30107.
    Abstract    



  106. BOKARICA P, Hrkac A, Gilja I
    Re: J. Alfred Witjes, Thierry Lebret, Eva M. Comperat, et al. Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Eur Urol 2017;71:462-75.
    Eur Urol. 2017 Mar 6. pii: S0302-2838(17)30126.
    Abstract    



  107. HUSSAIN SA, Palmer DH, Syn WK, Sacco JJ, et al
    Gene expression profiling in bladder cancer identifies potential therapeutic targets.
    Int J Oncol. 2017 Mar 2. doi: 10.3892/ijo.2017.3893.
    Abstract    

    Abstract available

  108. SHIMIZU F, Muto S, Taguri M, Ieda T, et al
    Effectiveness of platinum-based adjuvant chemotherapy for muscle-invasive bladder cancer: A weighted propensity score analysis.
    Int J Urol. 2017 Mar 9. doi: 10.1111/iju.13324.
    Abstract    

    Abstract available

  109. BOEHM BE, Cornell JE, Wang H, Mukherjee N, et al
    Efficacy of Bacillus Calmette-guerin Strains for the Treatment of non-muscle Invasive Bladder Cancer: a Systematic Review and Network Meta-analysis.
    J Urol. 2017 Mar 9. pii: S0022-5347(17)39246-7. doi: 10.1016/j.juro.2017.
    Abstract    

    Abstract available

  110. TOBERT CM, Hamilton-Reeves JM, Norian LA, Hung C, et al
    The Emerging Impact of Malnutrition on Surgical Patients: Literature Review and Potential Implications on Cystectomy for Bladder Cancer.
    J Urol. 2017 Mar 9. pii: S0022-5347(17)39247-9. doi: 10.1016/j.juro.2017.
    Abstract    

    Abstract available

  111. WAN W, Peng K, Li M, Qin L, et al
    Histone demethylase JMJD1A promotes urinary bladder cancer progression by enhancing glycolysis through coactivation of hypoxia inducible factor 1alpha.
    Oncogene. 2017 Mar 6. doi: 10.1038/onc.2017.
    Abstract    

    Abstract available

  112. HORI S, Miyake M, Onishi S, Tatsumi Y, et al
    Clinical significance of alpha and betaKlotho in urothelial carcinoma of the bladder.
    Oncol Rep. 2016;36:2117-25.
    Abstract    

    Abstract available

  113. ZHANG Y, Zhang Z, Li Z, Gong D, et al
    MicroRNA-497 inhibits the proliferation, migration and invasion of human bladder transitional cell carcinoma cells by targeting E2F3.
    Oncol Rep. 2016;36:1293-300.
    Abstract    

    Abstract available

  114. ZHANG N, Bi X, Zeng Y, Zhu Y, et al
    TGF-beta1 promotes the migration and invasion of bladder carcinoma cells by increasing fascin1 expression.
    Oncol Rep. 2016;36:977-83.
    Abstract    

    Abstract available

  115. YANG X, Zhang F, Luo J, Pang J, et al
    A new non-muscle-invasive bladder tumor-homing peptide identified by phage display in vivo.
    Oncol Rep. 2016;36:79-89.
    Abstract    

    Abstract available

  116. NAKAMURA Y, Yoshida S, Tanaka H, Inoue M, et al
    Potential Utility of Diffusion-Weighted Magnetic Resonance Imaging in Diagnosis of Residual Bladder Cancer before Second Transurethral Resection.
    Urol Int. 2017 Mar 1. doi: 10.1159/000456722.
    Abstract    

    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;